| 臺大學術典藏 |
2022-03-08T08:27:21Z |
The fungal metabolite, citrinin, inhibits lipopolysaccharide/interferon- γ-induced nitric oxide production in glomerular mesangial cells
|
Liu, Biing-Hui; Chi J.-Y.; Hsiao Y.-W.; Tsai K.-D.; Lee Y.-J.; Lin C.-C.; Hsu S.-C.; Yang S.-M.; Lin T.-H. |
| 臺大學術典藏 |
2022-03-08T03:44:07Z |
A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor
|
SHIH-HUNG YANG; Lin C.-C.; Lin Z.-Z.; Tseng Y.-L.; Hong R.-L. |
| 臺大學術典藏 |
2022-03-08T03:44:03Z |
A Phase i study of S-1-based concurrent chemoradiotherapy followed by gemcitabine and S-1 in metastatic pancreatic adenocarcinoma
|
SHIH-HUNG YANG; Shao Y.-Y.; Lin C.-C.; Kuo S.-H.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2022-03-04T08:22:50Z |
Annular esophageal leiomyoma mimicking a foregut cyst on endoscopic ultrasound
|
Lin C.-C.; JYH-CHIN YANG; Wang H.-P.; Lee J.-M.; Liu K.-L. |
| 臺大學術典藏 |
2022-03-04T08:22:48Z |
Identification of 14-3-3β in human gastric cancer cells and its potency as a diagnostic and prognostic biomarker
|
Tseng C.-W.; JYH-CHIN YANG; Chen C.-N.; Huang H.-C.; Chuang K.-N.; Lin C.-C.; Lai H.-S.; Lee P.-H.; Chang K.-J.; Juan H.-F. |
| 臺大學術典藏 |
2022-03-04T05:33:28Z |
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Su K.-Y.; Chang Y.-L.; CHEN-TU WU; Hsu C.-C.; Liao B.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-03-04T05:33:27Z |
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib
|
Yang C.-Y.; Liao W.-Y.; Ho C.-C.; Chen K.-Y.; Tsai T.-H.; Hsu C.-L.; Liu Y.-N.; Su K.-Y.; Chang Y.-L.; CHEN-TU WU; Liao B.-C.; Hsu C.-C.; Hsu W.-H.; Lee J.-H.; Lin C.-C.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J. |
| 臺大學術典藏 |
2022-03-01T08:20:14Z |
General anesthesia with propofol (continuous intravenous infusion) supplemented with nitrous oxide: comparison with isoflurane.
|
Huang F.Y.; Huang H.H.; Lun K.C.; Lin Y.S.; MING-JIUH WANG; Lin C.C.; Hou W.Y.; Chen C.L.; Shin L.T.; Chao C.C. |
| 臺大學術典藏 |
2022-02-23T02:19:35Z |
Dimethylarginine Dimethylaminohydrolase 1 Polymorphisms and Venous Intimal Hyperplasia in Hemodialysis Patients
|
CHIH-CHENG WU; Hsieh M.-Y.; Lee C.-K.; Chuang S.-Y.; Chung M.-Y.; Lin C.-C. |
| 臺大學術典藏 |
2022-02-23T02:19:34Z |
Drug-coated balloon versus conventional balloon angioplasty of hemodialysis arteriovenous fistula or graft: A systematic review and meta-analysis of randomized controlled trials
|
Liao M.-T.; Chen M.-K.; Hsieh M.-Y.; Yeh N.-L.; Chien K.-L.; Lin C.-C.; CHIH-CHENG WU; Chie W.-C. |
| 臺大學術典藏 |
2022-02-23T02:19:32Z |
Semiparametric mixture cure model analysis with competing risks data: Application to vascular access thrombosis data
|
Chen C.-M.; Shen P.-S.; Lin C.-C.; CHIH-CHENG WU |
| 臺大學術典藏 |
2022-02-23T02:19:31Z |
Correction to: Semiparametric mixture cure model analysis with competing risks data: Application to vascular access thrombosis data (Statistics in Medicine, (2020), 39, 27, (4086-4099), 10.1002/sim.8711)
|
Chen C.-M.; Shen P.-S.; Lin C.-C.; CHIH-CHENG WU |
| 臺大學術典藏 |
2022-02-23T02:19:30Z |
Stent grafts improved patency of ruptured hemodialysis vascular accesses
|
Liao M.-T.; Luo C.-M.; Hsieh M.-C.; Hsieh M.-Y.; Lin C.-C.; Chie W.-C.; Yang T.-F.; CHIH-CHENG WU |
| 臺大學術典藏 |
2022-02-23T02:12:38Z |
Diffuse intraperitoneal metastasis after spontaneous rupture of hepatocellular carcinoma
|
Lin C.-C.; CHIEN-HUNG CHEN; Tsang Y.-M.; Jan I.-S.; Sheu J.-C. |
| 臺大學術典藏 |
2022-02-23T02:12:34Z |
Clinical manifestations and survival of hepatocellular carcinoma patients with peritoneal metastasis
|
Lin C.-C.; Liang H.-P.; Lee H.-S.; Huang G.-T.; Yang P.-M.; Ho M.-C.; Lee P.-H.; Tsang Y.-M.; Chen D.-S.; Sheu J.-C.; CHIEN-HUNG CHEN |
| 臺大學術典藏 |
2022-02-23T02:12:24Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Lu S.-N.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; CHIEN-HUNG CHEN; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; Cheng A.-L.; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2022-02-23T02:12:17Z |
Tenofovir Is Superior to Entecavir on Tertiary Prevention for BCLC Stage 0/A Hepatocellular Carcinoma after Curative Resection
|
Tsai M.-C.; Wang C.-C.; Lee W.-C.; Lin C.-C.; Chang K.-C.; CHIEN-HUNG CHEN; Hung C.-H.; Lin M.-T.; Hsiao C.-C.; Chen C.-L.; Chien R.-N.; Hu T.-H. |
| 臺大學術典藏 |
2022-02-22T05:34:33Z |
Diffuse intraperitoneal metastasis after spontaneous rupture of hepatocellular carcinoma
|
Lin C.-C.; CHIEN-HUNG CHEN; Tsang Y.-M.; Jan I.-S.; Sheu J.-C. |
| 臺大學術典藏 |
2022-02-22T05:34:27Z |
Clinical manifestations and survival of hepatocellular carcinoma patients with peritoneal metastasis
|
Lin C.-C.; Liang H.-P.; Lee H.-S.; Huang G.-T.; Yang P.-M.; Ho M.-C.; Lee P.-H.; Tsang Y.-M.; Chen D.-S.; Sheu J.-C.; CHIEN-HUNG CHEN |
| 臺大學術典藏 |
2022-02-22T05:34:15Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Lu S.-N.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; CHIEN-HUNG CHEN; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; Cheng A.-L.; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2022-02-22T05:34:07Z |
Tenofovir Is Superior to Entecavir on Tertiary Prevention for BCLC Stage 0/A Hepatocellular Carcinoma after Curative Resection
|
Tsai M.-C.; Wang C.-C.; Lee W.-C.; Lin C.-C.; Chang K.-C.; CHIEN-HUNG CHEN; Hung C.-H.; Lin M.-T.; Hsiao C.-C.; Chen C.-L.; Chien R.-N.; Hu T.-H. |
| 臺大學術典藏 |
2022-02-21T03:52:39Z |
Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer
|
JIH-HSIANG LEE; Lin Y.-L.; Hsu W.-H.; Chen H.-Y.; Chang Y.-C.; Yu C.-J.; Shih J.-Y.; Lin C.-C.; Chen K.-Y.; Ho C.-C.; Laio W.-Y.; Yang P.-C.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-02-21T03:52:38Z |
Safety of gefitinib in non-small cell lung cancer treatment
|
Hsiue E.H.-C.; JIH-HSIANG LEE; Lin C.-C.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-02-21T03:52:38Z |
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis
|
Liao B.-C.; JIH-HSIANG LEE; Lin C.-C.; Chen Y.-F.; Chang C.-H.; Ho C.-C.; Shih J.-Y.; Yu C.-J.; Yang J.C.-H. |
| 臺大學術典藏 |
2022-02-21T03:52:37Z |
Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors
|
Liao B.-C.; Lin C.-C.; JIH-HSIANG LEE; Yang J.C.-H. |
